Power priors and type I error control: constrained borrowing of external control data.

Recently, hybrid designs have garnered significant attention in the healthcare industry due to their potential to improve statistical power and trial efficiency by augmenting randomized controlled trial data with external controls. The power prior methodology provides a versatile framework for constructing and analyzing data from hybrid designs. However, the use of external control data poses a risk of introducing bias, particularly in the presence of prior-data conflict, which can distort treatment effect estimates. Such biases may lead to erroneous conclusions, including the approval of ineffective treatments or the rejection of beneficial ones. To address these concerns, it is essential to borrow an appropriate amount of external data to maintain the type I error rate at an acceptable level, typically determined during trial planning in discussion with regulatory authorities. In this article, we present a novel power prior method to incorporate historical control data while safeguarding against inflation of the type I error rate beyond the maximally allowable nominal level. Through comprehensive simulation studies and an illustrative example, we demonstrate the practical advantages of our approach. The results illustrate that our method provides trial sponsors with a scientifically rigorous strategy for leveraging external control data in constructing efficient and reliable hybrid designs.

• Publication year

  2025

• Venue

  Journal of Biopharmaceutical Statistics

• Publication date

  2025-11-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/10543406.2025.2575940PMID 41225727
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Using Bayesian statistics in confirmatory clinical trials in the regulatory setting: a tutorial review

  2024cited by this paper
• Streamlining Randomized Clinical Trials for Device Therapies in Heart Failure: Bayesian Borrowing of External Data.

  2024cited by this paper
• Decoupling power and type I error rate considerations when incorporating historical control data using a test‐then‐pool approach

  2024cited by this paper
• Eliciting the Discount Parameter in a Power Prior Method on the Basis of the Type I Error Consideration

  2024cited by this paper
• Perspectives on informative Bayesian methods in pediatrics

  2023cited by this paper
• Beyond the Classical Type I Error: Bayesian Metrics for Bayesian Designs Using Informative Priors

  2023cited by this paper
• Real-World Evidence in Medical Product Development

  2023cited by this paper
• Covariate handling approaches in combination with dynamic borrowing for hybrid control studies

  2023cited by this paper
• Using Bayesian Dynamic Borrowing to Maximize the Use of Existing Data: A Case-Study

  2023cited by this paper
• Comparative Study of Bayesian Information Borrowing Methods in Oncology Clinical Trials

  2022cited by this paper
• Challenges and potential strategies utilizing external data for efficacy evaluation in small-sized clinical trials

  2022cited by this paper
• Exploring the Potential of External Control Arms created from Patient Level Data: A case study in non-small cell lung cancer

  2022cited by this paper
• Normalized Power Prior Bayesian Analysis

  2022cited by this paper
• Addressing statistical issues when leveraging external control data in pediatric clinical trials using Bayesian dynamic borrowing

  2022cited by this paper
• On the use of non-concurrent controls in platform trials: a scoping review

  2022cited by this paper
• A Propensity-Score Integrated Approach to Bayesian Dynamic Power Prior Borrowing

  2022cited by this paper
• The design and evaluation of hybrid controlled trials that leverage external data and randomization

  2022cited by this paper
• Augmenting Randomized Clinical Trial Data with Historical Control Data: Precision Medicine Applications.

  2022cited by this paper
• Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer

  2022cited by this paper
• Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis.

  2022cited by this paper
• A re-examination of the SPYRAL HTN-OFF MED Pivotal trial with respect to the underlying model assumptions

  2021cited by this paper
• Assessments of Conditional and Unconditional Type I Error Probabilities for Bayesian Hypothesis Testing with Historical Data Borrowing

  2021cited by this paper
• Dynamic borrowing from a single prior data source using the conditional power prior

  2021cited by this paper
• Optimising the trade‐off between type I and II error rates in the Bayesian context

  2021cited by this paper
• Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial.

  2020cited by this paper
• A roadmap to using historical controls in clinical trials – by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG)

  2020cited by this paper
• Causal Inference Methods for Combining Randomized Trials and Observational Studies: A Review.

  2020cited by this paper
• Improving efficiency of inference in clinical trials with external control data

  2020cited by this paper
• A BAYESIAN ADAPTIVE TWO-STAGE DESIGN FOR PEDIATRIC CLINICAL TRIALS

  2020cited by this paper
• Revisit of test‐then‐pool methods and some practical considerations

  2020cited by this paper
• Power gains by using external information in clinical trials are typically not possible when requiring strict type I error control

  2019cited by this paper
• Bayesian clinical trial design using historical data that inform the treatment effect.

  2019cited by this paper
• Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review

  2019cited by this paper
• Predictively consistent prior effective sample sizes

  2019cited by this paper
• Quantification of prior impact in terms of effective current sample size

  2019cited by this paper
• Propensity score-integrated power prior approach for incorporating real-world evidence in single-arm clinical studies

  2019cited by this paper
• Bayesian design of a survival trial with a cured fraction using historical data

  2018cited by this paper
• Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016

  2018cited by this paper
• Dynamic borrowing through empirical power priors that control type I error

  2018cited by this paper
• Parents' perceived obstacles to pediatric clinical trial participation: Findings from the clinical trials transformation initiative

  2017cited by this paper
• Including historical data in the analysis of clinical trials: Is it worth the effort?

  2017cited by this paper
• Supplementation of a clinical trial by historical control data: is the prospect of dynamic borrowing an illusion?

  2017cited by this paper
• Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation

  2017cited by this paper
• International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia

  2016cited by this paper
• ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

  2016cited by this paper
• Pragmatic Trials.

  2016cited by this paper
• The ADAPTABLE Trial and PCORnet: Shining Light on a New Research Paradigm

  2015cited by this paper
• Adaptive sample size modification in clinical trials: start small then ask for more?

  2015cited by this paper
• The power prior: theory and applications

  2015cited by this paper
• Use of historical control data for assessing treatment effects in clinical trials

  2014cited by this paper
• Robust meta‐analytic‐predictive priors in clinical trials with historical control information

  2014cited by this paper
• Thrombus aspiration during ST-segment elevation myocardial infarction.

  2013cited by this paper
• Adaptive adjustment of the randomization ratio using historical control data

  2013cited by this paper
• Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials

  2011cited by this paper
• Adaptive increase in sample size when interim results are promising: A practical guide with examples

  2011cited by this paper
• Summarizing historical information on controls in clinical trials

  2010cited by this paper
• Matching methods for causal inference: A review and a look forward.

  2010cited by this paper
• A note on the power prior

  2009cited by this paper
• Optimising the design of phase II oncology trials: the importance of randomisation.

  2009cited by this paper
• Determining the Effective Sample Size of a Parametric Prior

  2008cited by this paper
• Experience with Reviewing Bayesian Medical Device Trials

  2007cited by this paper
• Bayesian clinical trials

  2006cited by this paper
• On Optimality Properties of the Power Prior

  2003cited by this paper
• Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes

  2003cited by this paper
• Power prior distributions for regression models

  2000cited by this paper
• Regression Shrinkage and Selection via the Lasso

  1996cited by this paper
• Childhood-onset schizophrenia: the severity of premorbid course.

  1995cited by this paper
• An Introduction to Empirical Bayes Data Analysis

  1985cited by this paper
• Historical versus randomized controls for clinical trials

  1980cited by this paper
• The combination of randomized and historical controls in clinical trials.

  1976cited by this paper
• Testing Statistical Hypotheses

  1959cited by this paper

• No citing papers are available for this paper.